Albany, Feb 7, 2019 (Issuewire.com) - Venous Thromboembolism - Market Insight, Epidemiology and Market Forecast - 2027

Venous thromboembolism (VTE) is a common disorder with at least 250,000 new events occurring each year in the United States.

• Thromboembolism has a significant impact on morbidity and mortality internationally. A multinational report of European Union countries estimated that the total number of symptomatic, nonfatal VTE events per annum was more than 465,000 cases of DVT and more than 295,000 cases of PE.
• The estimated annual average rate (for years 2007-2009) of hospitalizations in which VTE was diagnosed was as follows for specific adult age groups:

Aged 18-39 - 60/100,000 population

Aged 40-49 - 143/100,000 population

Aged 50-59 years - 200/100,000 population

Aged 60-69 years - 391/100,000

Aged 70-79 years - 727/100,000

Aged 80 years or older - 1134/100,000

• Over a 3-year period (2007-2009), there was an estimated annual average of 547,596 hospitalizations in which VTE was diagnosed, for patients aged 18 years or older.

(Albany, US) DelveInsight launched a new report on Venous Thromboembolism - Market Insight, Epidemiology and Market Forecast - 2027

Key topics covered

• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Venous Thromboembolism market
• Organize sales and marketing efforts by identifying the best opportunities for Venous Thromboembolism market
• To understand the future market competition in the Venous Thromboembolism market.

Over the same period, for the same age group, an estimated average of 348,558 hospitalizations in which DVT was diagnosed annually, and an estimated average of 277,549 hospitalizations in which PE was diagnosed annually. Among these patients, an estimated average of 78,511 hospitalizations in which both DVT and PE were diagnosed annually.

Venous thromboembolism is a life-threatening medical condition that requires immediate medical treatment. Treatment primarily focuses on breaking the clots and preventing further formation of clots. Treatment of Venous thromboembolism includes blood thinning agents such as Medication (Anticoagulants, Thrombolytic Agents, Factor Xa Inhibitors, Thrombin Inhibitors). Mechanical devices (compression stockings), and Surgical treatment (Pulmonary embolectomy, Vena caval interruption) are also used in advances stages of Venous thromboembolism.

Medical therapy for the treatment of Venous thromboembolism includes:  

• Anticoagulants (Heparin, Warfarin, Enoxaparin, Dalteparin), Thrombolytic Agents (Reteplase and Tenecteplase) Factor Xa Inhibitors such as Apixaban, Rivaroxaban, Edoxaban, Betrixaban Thrombin Inhibitors such as Dabigatran.

Companies covered

• Eisai
• Portola Pharmaceuticals
• Daiichi Sankyo, Inc
• Boehringer Ingelheim Pharmaceuticals

And  many others

       Drugs covered

• Bevyxxa
• FRAGMIN
• Savaysa
• PRADAXA

And many others

 Table of contents

• Report Introduction
  2. Venous Thromboembolism Market Overview at a Glance
  2.1. Market Share Distribution of Venous Thromboembolism in 2017
  2.2. Market Share Distribution of Venous Thromboembolism in 2027
  3. Disease Background and Overview: Venous Thromboembolism
  3.1. Introduction
  3.2. Symptoms
  3.3. Etiology
  3.4. Risk Factors
  3.5. Pathophysiology
  3.6. Diagnosis
  3.7. Treatment
  4. Epidemiology and Patient Population
  4.1. Key Findings
  4.2. Total Prevalent/ Incident Patient Population of Venous Thromboembolism in 7MM
  4.3. Total Prevalent Patient Population of Venous Thromboembolism in 7MM Â By Countries
  5. Epidemiology of Venous Thromboembolism by Countries
  5.1. United States
  5.1.1. Assumptions and Rationale
  5.1.2. Prevalent/Incident Cases of the Venous Thromboembolism
  5.1.3. Sub-Type Specific cases of the Venous Thromboembolism
  5.1.4. Sex- Specific Cases of the Venous Thromboembolism
  5.1.5. Diagnosed Cases of the Venous Thromboembolism
  5.1.6. Treatable Cases of the Venous Thromboembolism
  5.2. EU5
  5.3. Assumptions and Rationale
  5.4. Germany
  5.4.1. Assumptions and Rationale
  5.4.2. Prevalent/Incident Cases of the Venous Thromboembolism
  5.4.3. Sub-Type Specific cases of the Venous Thromboembolism
  5.4.4. Sex- Specific Cases of the Venous Thromboembolism
  5.4.5. Diagnosed Cases of the Venous Thromboembolism
  5.4.6. Treatable Cases of the Venous Thromboembolism
  5.5. France
  5.5.1. Assumptions and Rationale
  5.5.2. Prevalent/Incident Cases of the Venous Thromboembolism
  5.5.3. Sub-Type Specific cases of the Venous Thromboembolism
  5.5.4. Sex- Specific Cases of the Venous Thromboembolism
  5.5.5. Diagnosed Cases of the Venous Thromboembolism
  5.5.6. Treatable Cases of the Venous Thromboembolism
  5.6. Italy
  5.6.1. Assumptions and Rationale
  5.6.2. Prevalent/Incident Cases of the Venous Thromboembolism
  5.6.3. Sub-Type Specific cases of the Venous Thromboembolism
  5.6.4. Sex- Specific Cases of the Venous Thromboembolism
  5.6.5. Diagnosed Cases of the Venous Thromboembolism
  5.6.6. Treatable Cases of the Venous Thromboembolism
  5.7. Spain
  5.7.1. Assumptions and Rationale
  5.7.2. Prevalent/Incident Cases of the Venous Thromboembolism
  5.7.3. Sub-Type Specific cases of the Venous Thromboembolism
  5.7.4. Sex- Specific Cases of the Venous Thromboemolism
  5.7.5. Diagnosed Cases of the Venous Thromboembolism
  5.7.6. Treatable Cases of the Venous Thromboembolism
  5.8. United Kingdom
  5.8.1. Assumptions and Rationale
  5.8.2. Prevalent/Incident Cases of the Venous Thromboembolism
  5.8.3. Sub-Type Specific cases of the Venous Thromboembolism
  5.8.4. Sex- Specific Cases of the Venous Thromboembolism
  5.8.5. Diagnosed Cases of the Venous Thromboembolism
  5.8.6. Treatable Cases of the Venous Thromboembolism
  5.9. Japan
  5.9.1. Assumptions and Rationale
  5.9.2. Prevalent/Incident Cases of the Venous Thromboembolism
  5.9.3. Sub-Type Specific cases of the Venous Thromboembolism
  5.9.4. Sex- Specific Cases of the Venous Thromboembolism
  5.9.5. Diagnosed Cases of the Venous Thromboembolism
  5.9.6. Treatable Cases of the Venous Thromboembolism
  6. Current Treatment & Medical practices
  6.1. Treatment Algorithm
  6.2. Treatment Guidelines
  7. Unmet Needs of the Venous Thromboembolism
  8. Marketed Therapies
  8.1. Drug A: Company 1
  8.1.1. Drug Description
  8.1.2. Mechanism of Action
  8.1.3. Regulatory Milestones
  8.1.4. Advantages & Disadvantages
  8.1.5. Product Profile
  8.2. Drug B: Company 2
  8.2.1. Drug Description
  8.2.2. Mechanism of Action
  8.2.3. Regulatory Milestones
  8.2.4. Advantages & Disadvantages
  8.2.5. Product Profile
  9. Pipeline Therapies - At a glance
  10. Key Cross Competition
  11. Emerging Therapies for Venous Thromboembolism
  11.1. Drug C: Company 3
  11.1.1. Drug Description
  11.1.2. Clinical Trials Details
  11.1.3. Safety and Efficacy Profile
  11.1.4. Advantages & Disadvantages
  11.1.5. Pipeline Development Activities
  11.1.6. Product Profile
  11.2. Drug D: Company 4
  11.2.1. Drug Description
  11.2.2. Clinical Trials Details
  11.2.3. Safety and Efficacy Profile
  11.2.4. Advantages & Disadvantages
  11.2.5. Pipeline Development Activities
  11.2.6. Product Profile
  12. Venous Thromboembolism : 7MM Market Analysis
  12.1. 7MM Market Size of Venous Thromboembolism
  12.2. 7MM Percentage Share of drugs marketed for Venous Thromboembolism
  12.3. 7MM Market Sales of Venous Thromboembolism by Products
  13. Venous Thromboembolism : Country-Wise Market Analysis
  13.1. United States
  13.1.1. Market Size of Venous Thromboembolism in United States
  13.1.2. Percentage Share of drugs marketed for Venous Thromboembolism in United States
  13.1.3. Market Sales of Venous Thromboembolism by Products in United States
  13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
  13.2. EU-5
  13.2.1. Germany
  13.2.1.1. Market Size of Venous Thromboembolism in Germany
  13.2.1.2. Percentage Share of drugs marketed for Venous Thromboembolism in Germany
  13.2.1.3. Market Sales of Venous Thromboembolism by Products in Germany
  13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
  13.2.2. France
  13.2.2.1. Market Size of Venous Thromboembolism in France
  13.2.2.2. Percentage Share of drugs marketed for Venous Thromboembolism in France
  13.2.2.3. Market Sales of Venous Thromboembolism by Products in France
  13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
  13.2.3. Italy
  13.2.3.1. Market Size of Venous Thromboembolism in Italy
  13.2.3.2. Percentage Share of drugs marketed for Venous Thromboembolism in Italy
  13.2.3.3. Market Sales of Venous Thromboembolism by Products in Italy
  13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
  13.2.4. Spain
  13.2.4.1. Market Size of Venous Thromboembolism in Spain
  13.2.4.2. Percentage Share of drugs marketed for Venous Thromboembolism in Spain
  13.2.4.3. Market Sales of Venous Thromboembolism by Products in Spain
  13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
  13.2.5. United Kingdom
  13.2.5.1. Market Size of Venous Thromboembolism in United Kingdom
  13.2.5.2. Percentage Share of drugs marketed for Venous Thromboembolism in United Kingdom
  13.2.5.3. Market Sales of Venous Thromboembolism by Products in United Kingdom
  13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
  13.3. Japan
  13.3.1. Market Size of Venous Thromboembolism in Japan
  13.3.2. Percentage Share of drugs marketed for Venous Thromboembolism in Japan
  13.3.3. Market Sales of Venous Thromboembolism by Products in Japan
  13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
  14. Market Drivers
  15. Market Barriers
  16. Appendix
  17. Report Methodology
  17.1. Sources
  18. DelveInsight Capabilities
  19. Disclaimer
  20. About DelveInsight

Media Contact

Delveinsight Business Reserarch LLP

info@delveinsight.com

9193216187

304 S. Jones Blvd #2432, Las Vegas NV 89107

https://www.delveinsight.com/